The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...
The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417; BeOne ...
Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma. Calquence (acalabrutinib) plus standard-of-care ...
A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...
Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...
(Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating ...
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with ...
Mantle cell lymphoma (MCL) is often an aggressive form of cancer traditionally treated with chemotherapy, immunotherapy, and stem cell transplants when appropriate. Emerging therapies may offer more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback